Erratum: Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain-A case series (Scandinavian Journal of Pain (2013) (3-7) DOI: 10.1016/j.sjpain.2012.11.011);Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain-A case series

Scandinavian Journal of Pain

Volumn 4, Issue 1, 2013, Pages 3-7

  Kersten, Christian ^a   Cameron, Marte Grønlie ^a   Mjåland, Svein ^a  

^a Center for Cancer Treatment   (Norway)

Author keywords

Chronic pain; EGFR inhibition; Neuropathic pain

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CETUXIMAB; CLONIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GABAPENTIN; GEFITINIB; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PANITUMUMAB; PARACETAMOL; PREGABALIN; STEROID;

ADULT; AGED; ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; BLADDER CANCER; CASE STUDY; CLINICAL ARTICLE; COMPLEX REGIONAL PAIN SYNDROME TYPE I; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FAILED BACK SURGERY SYNDROME; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY POLYNEUROPATHY; LUMBOSACRAL PLEXUS; MALE; METASTASIS; NEUROPATHIC PAIN; PAIN ASSESSMENT; PHANTOM PAIN; POLYNEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADICULOPATHY; RATING SCALE; SELF REPORT; TREATMENT RESPONSE;

EID: 84872370609     PISSN: 18778860     EISSN: 18778879     Source Type: Journal    
DOI: 10.1016/j.sjpain.2013.02.001     Document Type: Erratum

References (24)

1. Jensen T.S., Baron R., Haanpää M., Kalso E., Loeser J.D., Rice A.S., Treede R.D. A new definition of neuropathic pain. Pain 2011, 152:2204-2205.
2. Finnerup N.B., Sindrup S.H., Jensen T.S. The evidence for pharmacological treatment of neuropathic pain. Pain 2010, 150:573-581.
3. Jensen M.P., Chodroff M.J., Dworkin R.H. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007, 68:1178-1182.
4. Dieleman J.P., Kerklaan J., Huygen F.J., Bouma P.A., Sturkenboom M.C. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain 2008, 137:681-688.
5. Bouhassira D., Lantéri-Minet M., Attal N., Laurent B., Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008, 136:380-387.
6. Scholz J., Woolf C.J. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 2007, 10:1361-1368.
7. Ji R.R., Gereau R.W., Malcangio M., Strichartz G.R. MAP kinase and pain. Brain Res Rev 2009, 60:135-148.
8. Kersten C., Cameron M.G. Cetuximab alleviates neuropathic pain despite tumour progression. BMJ Case Rep 2012, 2012.
9. Yarden Y., Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012, 12:553-563.
10. Freynhagen R., Baron R., Gockel U., Tölle T.R. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006, 22:1911-1920.
11. Klepstad P., Loge J.H., Borchgrevink P.C., Mendoza T.R., Cleeland C.S., Kaasa S. The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients. J Pain Symptom Manage 2002, 24:517-525.
12. Keller S., Bann C.M., Dodd S.L., Schein J., Mendoza T.R., Cleeland C.S. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004, 20:309-318.
13. Feinstein T.M., Gibson M.K., Argiris A. Cetuximab-induced aseptic meningitis. Ann Oncol 2009, 20:1609-1610.
14. Basti S. Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs 2007, 30(Suppl. 1):S10-S16.
15. Ramanathan R.K. Alternative dosing schedules for cetuximab: a role for biweekly administration?. Clin Colorectal Cancer 2008, 7:364-368.
16. Saadeh C.E., Lee H.S. Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer. Ann Pharmacother 2007, 41:606-613.
17. Alvarenga M.L., Kikhney J., Hannewald J., Metzger A.U., Steffens K.J., Bomke J., Krah A., Wegener A. In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor. Anal Biochem 2012, 421:138-151.
18. Ma F., Zhang L., Westlund K.N. Trigeminal nerve injury ErbB3/ErbB2 promotes mechanical hypersensitivity. Anesthesiology 2012, 117(2):381-388.
19. Yasuda S., Sugiura H., Tanaka H., Takigami S., Yamagata K. p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases. Cent Nerv Syst Agents Med Chem 2011, 11:45-59.
20. Liu B., Neufeld A.H. Activation of epidermal growth factor receptors in astrocytes: from development to neural injury. J Neurosci Res 2007, 85:3523-3529.
21. Carroll S.L., Miller M.L., Frohnert P.W., Kim S.S., Corbett J.A. Expression of neuregulins and their putative receptors, ErbB2 and ErbB3, is induced during Wallerian degeneration. J Neurosci 1997, 17:1642-1659.
22. Calvo M., Zhu N., Grist J., Ma Z., Loeb J.A., Bennett D.L. Following nerve injury neuregulin-1 drives microglial proliferation and neuropathic pain via the MEK/ERK pathway. Glia 2011, 59:554-568.
23. Kanzaki H., Mizobuchi S., Obata N., Itano Y., Kaku R., Tomotsuka N., Nakajima H., Ouchida M., Nakatsuka H., Maeshima K., Morita K. Expression changes of the neuregulin 1 isoforms in neuropathic pain model rats. Neurosci Lett 2012, 508:78-83.
24. Oliveras-Ferraros C., Vazquez-Martin A., Queralt B., Adrados M., Ortiz R., Cufí S., Hernández-Yagüe X., Guardeño R., Báez L., Martin-Castillo B., Pérez-Martínez M.C., Lopez-Bonet E., De Llorens R., Bernadó L., Brunet J., Menendez J.A. Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux(R)) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models. Int J Oncol 2011, 39:1455-1479.